The science of mystical experience: what we can actually measure
212 replies · Science & Research
The mystical experience questionnaire (MEQ-30) is used in most major psilocybin trials. Scores on this scale predict therapeutic outcomes better than almost any other measure. Can someone explain what we're actually measuring and why it matters therapeutically?
The MEQ-30 measures six dimensions: transcendence of time and space, sense of deeply felt positive mood, feeling of sacredness/holiness, noetic quality (sense of encountering ultimate reality), paradoxicality (things that seem contradictory but both true), and ineffability (difficulty expressing in words). Complete mystical experience requires all dimensions above threshold.
Why it predicts outcomes: theorized mechanisms include the 'ego dissolution' hypothesis (temporary suspension of the self-referential processing that maintains depression/anxiety), increased psychological flexibility, and the deep reconsolidation of memories and self-concept during neuroplastic window. The mystical quality correlates with the intensity of these mechanisms.
Important caveat: the MEQ correlation with outcomes doesn't mean that more mystical = always better. Dose finding matters — overwhelming experiences at very high doses may not produce better outcomes than deeply therapeutic experiences at moderate doses. The therapeutic sweet spot appears to be meaningful intensity without overwhelm.
209 more replies — forum posting coming soon.